CLINICAL_TRIALS
trial_result
· 2016-11-03
Clinical Trial Update: PhII ICb With/Without Erbitux in MBC Pts [Phase 2]
Summary
Phase II trial evaluating an immune checkpoint blocker with or without Erbitux (cetuximab) in metastatic breast cancer; results were posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: US Oncology Research | Conditions: Metastatic Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2016-11-03